GOTHENBURG, Sweden, Feb. 7, 2002 (PRIMEZONE) -- Nobel Biocare:
-- Sales increased by 26% to SEK 2 663.2 million (2 109.5). Sales in
the fourth quarter amounted to SEK 754.1 million (634.8).
-- Operating income amounted to SEK 363.7 million (289.6). Operating
income before non-recurring items amounted to SEK 430.1 million
(267.3). The year-on-year currency effects were positive, SEK 23
million. Operating income before non-recurring items in the fourth
quarter amounted to SEK 136.1 million (123.7).
-- Cash flow from current operations amounted to SEK 684.4 million
(263.8).
-- Earnings per share amounted to SEK 7.45 (5.35).
-- Nobel Biocare AB acquired Sandvik AB's 50% share in the dental
technology company Procera Sandvik AB, on 27 December 2001.
-- Nobel Biocare's shares were upgraded to the Most Traded-segment of
the A-list on the Stockholm Stock Exchange, on 1 January 2002
SEK M Full year Full year Change
2001 2000
Net sales 2 663.2 2 109.5 +26.2%
of which Dental Implants 2 329.5 1 851.0 +25.9%
of which Procera(r) 333.7 258.5 +29.1%
Operating income before
goodwill amortization (EBITA) 494.5 326.4 +51.5%
Operating income (EBIT) 430.1 267.3 +60.9%
before non-recurring items
Non-recurring items -66.4 22.3 -
Operating income (EBIT) 363.7 289.6 +25.6%
Income before tax 339.0 247.8 +36.8%
Net income 189.0 134.1 +40.9%
Cash flow from current 684.4 263.8 +159.4%
operations
Earnings per share, SEK 7.45 5.35 +39.4%
Earnings per share excluding
goodwill amortization 12.62 6.82 +85.0%
Average number of shares 25 346 215 25 069 782
Market value 11 005 7 179
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download: www.waymaker.net/bitonline/2002/02/07/20020207BIT00030/bit0001.doc The full year-end report www.waymaker.net/bitonline/2002/02/07/20020207BIT00030/bit0001.pdf The full year-end report